Stem cell transplantation for metachromatic leukodystrophy: a family centered approach  by Maurice, L.C.
Transplant Nursing
255
ANALYSIS OF DISEASE BEHAVIOR OF PATIENTS WITH HEMATOPOIETIC
STEM CELL TRANSPLANTATION AND NURSING CARE
Su, R., Tang, Y.J. 301 Hospital, Beijing, China
Purpose To analysis the ill behavior of patients with hematopoi-
etic stem cell transplantation. Methods The questionmaire of ill
behavior was adopted and 17 patients with hematopoietic stem cell
transplantation were asked to answer the questions. Results Faith
in disease and belief in disease were both lower than normal
standards. The index of double in disease fell in the normal, but
their psychological orientation was higher. They were mentally
healthy like a non-disease person but carried special psychologic
behavior as patients with hematopoietic stem cell transplantation.
Conclusions It is necessary to education patients with hematopoi-
etic stem cell transplantation.
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STEM CELL TRANSPLANTATION FOR METACHROMATIC LEUKODYS-
TROPHY: A FAMILY CENTERED APPROACH
Maurice, L.C. Sydney Children’s Hospital, Sydney, NSW, Australia
At Sydney Children’s Hospital, Stem cell transplant is offered as
a potential cure to children who suffer from certain malignant and
non-malignant diseases. When a family is confronted with the
same life threatening illness in two siblings, the devastation and
emotions are tremendous. As their 2-year-old daughter is diag-
nosed with Metachromatic leukodystrophy (MLD) the future of
the unborn sibling remains unclear. As the family is told that
curative treatment can only be offered to one sibling, they must
simultaneously prepare for the inevitable death of the other.
This presentation will discuss the management of an infant un-
dergoing a stem cell transplant at the age of 6 weeks, whilst his
sister is receiving palliative care for the same disease. Metachro-
matic leukodystrophy is an autosomal recessive lysosomal storage
disorder occurring in 1: 40 000 births. It is characterised by the
accumulation of lipid (sulfatide) primarily in the central nervous
system resulting in progressive neurodegenerative function. MLD
is caused by the deﬁciency of the enzyme arylsulfatase which is
responsible for the breakdown of sulfatide.
During the last decade, stem cell transplantation has been used
successfully to correct several genetic metabolic disorders by re-
placing cells of haematopoietic origin that can restore the deﬁcient
enzymes in the recipient. The most common variety of MLD
appears in early childhood, but the disease may also occur in adults.
It usually leads to progressive paralysis and, in children, early death
occurs.
The advances in diagnostic medicine made it possible to diagnose
the newborn within weeks of life, offering the family some hope of
cure. This presentation will discuss the approach the health care
team took in looking after a transplant family who are on such a
huge roller coaster ride, and it will describe how this family was
managed on the transplant unit.
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TO BLEED OR NOT TO BLEED? THAT IS THE QUESTION (NURSING
MANAGEMENT OF PATIENT WITH HEMORRHAGIC CYSTITIS POST BMT)
Dela Cruz, B.P. MD Anderson Cancer Center, Houston, TX
Hemorrhagic cystitis is a syndrome of hematuria with symptoms
of urinary tract irritability indicated by dysuria, frequency and
urgency. Incidence varies according to conditioning regimen, pre-
ventative measures employed, and graft versus host disease pro-
phylaxis used. There are two types of occurrences: 1. Early onset
happens during or shortly after the conditioning regimen in which
patients may have received cyclophosphamide, ifosphamide or
busulfan. 2. Late onset occurs weeks to months after bone marrow
transplant related to contraction of certain viruses.
BMT patient who are immunocompromised, viruses are reacti-
vated and excreted in the urine. In general viral shredding occurs
2-8 weeks after BMT and resolves spontaneously within three
weeks. Another risk factor that contributes to hemorrhagic cystitis
is GVHD. The bladder epithelium is a target organ for GVHD to
attack and immunosuppressed patients already having associated
complications with GVHD have an increased risk for acquiring
viral infections.
Standard treatment modalities of hemorrhagic cystitis are: 1.
Hydrating patients with intravenous and oral ﬂuids. 2. Continuous
bladder irrigation. 3. Bladder Instillation with Alum, Carboprost,
silver nitrate, phenol, prostaglandin, and hydrocortisone. 4. Giving
smooth muscle relaxants for bladder spasms. 5. Antiviral therapy. 6.
Cystoscopy. 7. Our center is studying NOVO-seven injections to
help with the clotting mechanism.
The nurses have an essential role in early detection. Mnemonics
that would assist nurses in patient assessment is “U PAAS BI.”
U-urinary output, P-pain management, A–assessment of urine,
S–specimen collection for urine cytology, B–blood counts and
I-infusion of blood products as necessary.
Chemotherapy and viruses may account for a substantial propor-
tion of late onset and long lasting hemorrhagic cystitis in BMT
patients. In conclusion, nursing plays a huge role in prevention,
early detection and treatment of hemorrhagic cystitis.
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THE DEVELOPMENT OF A NEED ASSESSMENT TOOL FOR FAMILIES OF
BMT PATIENTS
Lee, Y.-S.1, Tak, Y.-R.2, Yun, E.-W.2, Lee, K.-H.1, Lee, J.-H.1, Choi,
S.-J.1, Seol, M.1, Lee, J.-S.1 1. Asan Medical Center, Seoul, Korea;
2. Hanyang University, Seoul, Korea
BMT is now mostly used to treat patients with advanced malig-
nancies. However, health care provider’s attention is prioritized
toward BMT patients for the BMT trajectory, although uncer-
tainty of survival, high cost, many physical changes of patient cause
signiﬁcant distress, anxiety, and burden on family. Preliminary
study ﬁndings suggested that needs of family of patient were
consisted with the needs for information, assurance, convenience,
proximity, and support. Therefore, this research was designed to
develop the need assessment tool that can be used for identifying
and assessing what are needs of family of BMT patients. The data
for the tool were collected from in-depth interview with family of
BMT patients, self-reports of health care provider, and literature
review. From the content analysis, the needs were identiﬁed as 61
items. In order to test reliability and factor analysis, 120 family
members of BMT patients were sampled from September 2001 to
July 2003 in Korea.
Results from factor analysis, 9 factors were conﬁrmed. Factor
1(Need for information of treatment procedure and patient’s
health status), Factor 2(Need for patient’s comfort), Factor 3(Need
for social support), Factor 4(Need for emotional support), Factor
5(Need for follow up care), Factor 6(Need for family’s conve-
nience), Factor 7(Need for self assurance), Factor 8(Need for
reliable relationship with medical staffs), and Factor 9(Need for
physical environment of BMT unit).
As results, the need assessment tool showed high reliability
(Chronbach’s alpha was .93) and exploring nine factors of needs for
the family with BMT patient. The assessed need of family of BMT
patients will guide health care providers for the family intervention
program, and to serve the effective and evidence based care for the
family with BMT patients.
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A SUPPORT NETWORK FOR PATIENTS AND FAMILIES AFTER BLOOD
AND MARROW TRANSPLANTATION
Anders, V.L. Johns Hopkins University, Baltimore, MD
Patients who are treated with blood and marrow transplantation
(BMT) may feel alone and isolated as they recover from this
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